A065660 Share Price Performance
Recent A065660 News & Updates
No updates
Anterogen.Co.,Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -241.87
- Gross Margin
- 35.32%
- Net Profit Margin
- -34.56%
- Debt/Equity Ratio
- 0%
Anterogen.Co.,Ltd. Competitors
About A065660
- Founded
- 2000
- Employees
- n/a
- CEO
- WebsiteView website
Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as stem cell media program set, a cosmetic raw material. In addition, the company offers stem cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -2.5%
- 3 Months: 19.7%
- 1 Year: 13.3%
- Year to Date: 27.4%
Over the last 7 days, the market has dropped 2.5%, driven by a loss of 8.3% in the Financials sector. In the last year, the market is actually up 13%. Earnings are forecast to grow by 22% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading